Global proteomic profiling of meningioma cohort
Ontology highlight
ABSTRACT:
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Brain, Epithelial Cell
DISEASE(S): Brain Cancer
SUBMITTER: 
Shuvolina Mukherjee
LAB HEAD: SANJEEVA SRIVASTAVA
PROVIDER: PXD014823 | Pride | 2020-08-27
REPOSITORIES: Pride
Similar Datasets
Project description:Comparison of the gene expression profiles with meningiomas of different grading. 24 primary meningioma cultures from surgical specimen were maintained to primary meningioma cultures.
2014-03-06 | E-GEOD-55609 | biostudies-arrayexpress
Project description:Genomic profiling of anaplastic meningioma can inform prognostic gene level alterations in lower-grade meningiomas, potentially reflecting evolution of anaplastic meningioma from lowergrade precursor tumours. Larger scale studies in paired primary and recurrent meningiomas are warranted to unravel the evolutionary path to anaplastic meningiomas and prognostic genomic alterations in detail
2021-05-04 | GSE173825 | GEO
Project description:Multiple stereotatically separate sites from human meningioma were processed for methlyation profiling Meningiomas are the most common primary intracranial tumors, but the molecular drivers of meningioma tumorigenesis are poorly understood. We hypothesized that investigating intratumor heterogeneity in meningiomas would elucidate biologic drivers and reveal new targets for molecular therapy. To test this hypothesis, we performed multiplatform molecular profiling of 86 spatially-distinct samples from 13 human meningiomas. Our data reveal that regional alterations in chromosome structure underlie clonal transcriptomic, epigenomic, and histopathologic signatures in meningioma. Stereotactic co-registration of sample coordinates to preoperative magnetic resonance images further demonstrated that high apparent diffusion coefficient (ADC) distinguished meningioma regions with proliferating cells enriched for developmental gene expression programs. To understand the function of these genes in meningioma, we developed a human cerebral organoid model of meningioma and validated the high ADC marker genes CDH2 and PTPRZ1 as potential targets for meningioma therapy using live imaging, single cell RNA sequencing, CRISPR interference, and pharmacology.
2020-06-17 | GSE151067 | GEO
Project description:Although meningiomas are one of the most frequent primary intracranial tumors, there are only a few studies dealing with gene regulation processes in meningiomas. MiRNAs are key regulators of gene expression and regulation and miRNA profiles offer themselves as biomarkers for cancer development and progression. To investigate the role of miRNAs during meningioma growth and progression, we compared expression of 1205 miRNAs in 55 meningioma samples of different tumor grades and histological subtypes. We were able to classify histological subtypes in WHO grade I meningiomas with up to 97% accuracy (meningothelial versus fibroblastic) and different WHO grades with up to 93% accuracy (WHO I versus WHO III). We found significant downregulation of miRNAs on chromosome 1p36 and within two large miRNA clusters on 14q32 in high grade meningiomas, two regions that are yet associated with meningioma progression. We also identified several miRNAs associated with epithelial to mesenchymal transition differentially expressed in meningothelial meningioma compared to fibroblastic meningioma. Combined, our data show that meningiomas of different WHO grades and histological subtypes show a specific miRNA expression profile. Some individual miRNAs can also serve as potential biomarkers for meningioma progression.
2014-12-31 | GSE50641 | GEO
Project description:Meningiomas are the most common primary intracranial tumors and are associated with inactivation of the tumor suppressor NF2/Merlin, but one-third of meningiomas retain Merlin expression and typically have favorable clinical outcomes. Biochemical mechanisms underlying Merlin-intact meningioma growth are incompletely understood, and non-invasive biomarkers that predict meningioma outcomes and could be used to guide treatment de-escalation or imaging surveillance of Merlin-intact meningiomas are lacking. Here we integrate single-cell RNA sequencing, proximity-labeling proteomic mass spectrometry, mechanistic and functional approaches, and magnetic resonance imaging (MRI) across meningioma cells, xenografts, and human patients to define biochemical mechanisms and an imaging biomarker that distinguish Merlin-intact meningiomas with favorable clinical outcomes from meningiomas with unfavorable clinical outcomes. We find Merlin drives meningioma Wnt signaling and tumor growth through a feed-forward mechanism that requires Merlin dephosphorylation on serine 13 (S13) to attenuate inhibitory interactions with β-catenin and activate the Wnt pathway. Meningioma MRI analyses of xenografts and human patients show Merlin-intact meningiomas with S13 phosphorylation and favorable clinical outcomes are associated with high apparent diffusion coefficient (ADC) on diffusionweighted imaging. In sum, our results shed light on Merlin posttranslational modifications that regulate meningioma Wnt signaling and tumor growth in tumors without NF2/Merlin inactivation. To translate these findings to clinical practice, we establish a non-invasive imaging biomarker that could be used to guide treatment de-escalation or imaging surveillance for patients with favorable meningiomas.
2024-07-04 | PXD053578 | Pride
Project description:We report DNA methylation profiling on 565 meningiomas integrated with genetic, transcriptomic, biochemical, proteomic, and single-cell approaches to show meningiomas are comprised of 3 groups with distinct clinical outcomes, biological drivers, and therapeutic vulnerabilities. Merlin-intact meningiomas have the best outcomes and are distinguished by NF2/Merlin regulation of glucocorticoid signaling, apoptosis, and susceptibility to cytotoxic therapy. Immune-enriched meningiomas have intermediate outcomes and are distinguished by immune infiltration, HLA expression, and lymphatic vessels. Hypermitotic meningiomas have the worst outcomes and are distinguished by convergent genetic and epigenetic mechanisms driving the cell cycle and resistance to cytotoxic therapy. Our results establish a framework for understanding meningioma biology, and provide a foundation for new meningioma treatments.
2022-01-10 | GSE183647 | GEO
Project description:Variability of meningioma growth, even within benign subgroup, makes some remain unaltered, while others grow fast despite an appended radiotherapy. Biomarkers that differentiate between less and more aggressive meningiomas would therefore have a significant clinical benefit in prediction of their biological behaviour. The aim of the study was to identify new candidate miRNAs enabling better and proper prediction of meningioma recurrence. We used miRNA 4.0 array (Applied Biosystems, Foster City, CA, USA) to detect miRNA profiles in 44 primary meningioma patients (19 with subsequent recurrence) and 5 healthy controls. Moreover, miRNA profiles were analyzed in 15 secondary meningiomas.
2019-02-15 | GSE126563 | GEO
Project description:Meningiomas are common brain tumors that are classified into three World Health Organization grades (Grade I: benign, Grade II: atypical and Grade III: malignant) and are molecularly ill-defined tumors. The purpose of this study was identify microRNA (miRNA) molecular signatures unique to the different grades of meningiomas correlating them to prognosis. We have used a miRNA expression microarray to show that meningiomas of all three grades fall into two main molecular groups designated “benign” and “malignant” meningiomas. While all typical meningiomas fall into the benign group and all anaplastic meningiomas fall into the malignant group, atypical meningiomas distribute into either one of these groups. We have identified a miRNA signature that distinguishes benign meningiomas from malignant meningiomas. We studied the gene expression profiles of 340 mammalian miRNAs in 37 primary meningioma tumors by means of DNA microarrays.
2011-01-02 | E-GEOD-19720 | biostudies-arrayexpress
Project description:Meningiomas, the most common primary brain tumours, are classified by the World Health Organization (WHO) into grades 1, 2, and 3. Some grade 1 tumours exhibit increased clinical aggressiveness with the biallelic mutation of Neurofibromatosis 2 (NF2) being the most frequent mutation reported. In our study, we analysed the most common driver mutations (NF2, AKT1, KLF4, and TRAF7) in meningioma by proteomics and genomics focussing on lower grade tumours. Our genomic data revealed co-occurrences of non-NF2 mutations in lower-grade meningiomas suggesting synergistic effects supporting tumour growth. NF2-/- meningiomas showed distinct proteomic clustering, with different mutations found in these clusters. Additionally, proteomics identified ANXA3 in NF2-/- meningioma and its role in proliferation was confirmed in grade1 and subsequently grade 3 tumours in vitro and with abolished growth when tested in meningioma mouse model. These findings highlight new targets in different meningioma backgrounds presenting ANXA3 as a potential therapeutic target for meningioma treatment
2025-07-02 | PXD058651 | Pride
Project description:Meningiomas, the most common primary brain tumours, are classified by the World Health Organization (WHO) into grades 1, 2, and 3. Some grade 1 tumours exhibit increased clinical aggressiveness with the biallelic mutation of Neurofibromatosis 2 (NF2) being the most frequent mutation reported. In our study, we analysed the most common driver mutations (NF2, AKT1, KLF4, and TRAF7) in meningioma by proteomics and genomics focussing on lower grade tumours. Our genomic data revealed co-occurrences of non-NF2 mutations in lower-grade meningiomas suggesting synergistic effects supporting tumour growth. NF2-/- meningiomas showed distinct proteomic clustering, with different mutations found in these clusters. Additionally, proteomics identified ANXA3 in NF2-/- meningioma and its role in proliferation was confirmed in grade1 and subsequently grade 3 tumours in vitro and with abolished growth when tested in meningioma mouse model. These findings highlight new targets in different meningioma backgrounds presenting ANXA3 as a potential therapeutic target for meningioma treatment.
2025-07-02 | PXD058653 | Pride